Deaths in cancer trials remain mystery for promising therapy
December 04, 2016
experimental CAR T-cell immunotherapy has shown dramatic results, including
long-term cures, for cancer patients with severe disease, but has also left puzzling
questions about deaths that have occurred during some tests, Bloomberg reports
in a story published by The Washington Post.
“It’s a double-edged sword,” Lewis Silverman, clinical director of Dana-Farber/Boston
Children’s Hematologic Malignancy Center, tells Bloomberg. “You have to get
through some bad side effects because that’s actually a sign that the CAR-T is
- Read the story. Other outlets that picked up the
story include the Chicago
Tribune and News
OK (The Oklahoman).